Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement ...


- 11 Janvier 2017 modifié le 1 Janvier 1970


- Takeda Invests $125 Million in Maverick, Including Exclusive Option-to-Acquire -

(BUSINESS WIRE)-- Maverick Therapeutics Inc., an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that they have entered a collaboration to develop Maverick's T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. ...

Source : http://me-newswire.net//news/19339/en...